Utility of Lesion Diameter in the Clinical Diagnosis of Cutaneous Melanoma
Naheed R. Abbasi(New York University), David Polsky(New York University), Dina Gutkowicz–Krusin(STRATA Skin Sciences (United States)), Martín C. Mihm(Harvard University), Alfred W. Kopf, Molly Yancovitz(New York University), Iman Osman(New York University), Darrell S. Rigel(The University of Texas Southwestern Medical Center), Víctor G. Prieto(The University of Texas MD Anderson Cancer Center), Roy King, Paul B. Googe, Robert J. Friedman(New York University), Katherine S. Panageas(Mayo Clinic)
Cited by 61
Related Papers
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
BRAF mutation predicts sensitivity to MEK inhibition
|Nature|2005|1.3k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
|Journal of Clinical Oncology|2015|1.1k
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|1999|763
Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
|Journal of Clinical Oncology|2006|620